Clinical trial
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for…
NCT00448240 · Henry Ford Health System, Other · Terminated
Key facts
| NCT number | NCT00448240 |
|---|---|
| Title | Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer |
| Official title | Erlotinib (Tarceva) Given Intermittently During First Line Standard Platinum Containing Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck |
| Lead sponsor | Henry Ford Health System, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Carcinoma, Squamous Cell |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 6 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Mar 16, 2007 |
| Last update posted | Mar 18, 2025 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: